AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Bicycle Therapeutics plc
Video analysis: BCYC
All videosNo video analysis for this stock yet. Request one from our team.
News: BCYC
Visa Inks $2.4 Billion Deal to Acquire Fraud Prevention Firm BioCatch
Visa is set to acquire Israel-based fraud intelligence company BioCatch for $2.4 billion. The all-cash deal, announced Monday (Aug. 3) aims to complement Visa's cyber, fraud, risk and security solutions and help clients protect themselves and customers from a growing range of fraud-related threats.
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June 30, 2026, and provided recent corporate updates. “We are pleased with the progress we made during the second quarter. Our financial discipline with refined focus on nuzefatide pevedotin and our nex.
Similar companies
-
Neumora Therapeutics, Inc. Common Stock
NMRA
·
NASDAQ
Compare
-
Omeros Corporation
OMER
·
NASDAQ
Compare
-
Lexicon Pharmaceuticals, Inc.
LXRX
·
NASDAQ
Compare
-
ADC Therapeutics S.A.
ADCT
·
New York Stock Exchange
Compare
-
Prothena Corporation plc
PRTA
·
NASDAQ
Compare
-
4D Molecular Therapeutics, Inc.
FDMT
·
NASDAQ
Compare